万基遗传 2026年季度报告

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the transition period fromtoCommission file number:0-26642 MYRIAD GENETICS, INC. (Exact name of registrant as specified in its charter) 87-0494517 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller Large accelerated filerNon-accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. As of May1, 2026, the registrant had 94,448,210 shares of $0.01 par value common stock outstanding. MYRIAD GENETICS, INC. INDEX TO FORM 10-Q PART I - Financial Information Item 1.Financial Statements Condensed Consolidated Balance Sheets as ofMarch31, 2026andDecember31, 2025(unaudited) Condensed Consolidated Statements of Comprehensive Income(Loss) for thethree months ended March 31,2026 and2025(unaudited)Condensed Consolidated Statements of Stockholders’ Equity for thethree months ended March 31, 2026and2025(unaudited)Condensed Consolidated Statements of Cash Flows for thethree months ended March 31, 2026and2025(unaudited)Notes to Condensed Consolidated Financial Statements (unaudited)Item 2.Management's Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures PART II - Other Information Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures 27 28 PART I - Financial Information MYRIAD GENETICS, INC. AND SUBSIDIARIES MYRIAD GENETICS, INC. MYRIAD GENETICS, INC. AND SUBSIDIARIES MYRIAD GENETICS, INC. AND SUBSIDIARIES MYRIAD GENETICS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 1.BASIS OF PRESENTATION Myriad Genetics, Inc. (together with its subsidiaries, the “Company” or “Myriad”) is a leading molecular diagnostics and precisionmedicine company committed to advancing health and well-being for all. The Company develops and commercializes molecular teststhat help patients and providers uncover genetic insights. Myriad tests assess the risk of developing disease or disease progression andguide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with UnitedStates ("U.S.") generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicablerules and regulations of the Securities and Exchange Commission (“SEC”).All intercompany accounts and transactions have beeneliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affectthe reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, The Company has historically experienced some seasonality in its business, including due to factors such as the timing of deductiblesresetting or being met. While the Company continues to experience periodic fluctuations in quarterly revenues, these variations areincreasingly influenced by other factors such as the timing of customer activity, reimbursement dynamics, and broader market Recent Accounting Pronouncements In September 2025, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2025-07, Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements andScope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract.The guidance in ASU 2025-07refines the scope of derivative accounting under Accounting Standards Codification ("ASC") 815 by expanding an existing scopeexception to exclude certain non-exchange traded contracts with underlyings based on the operations or activities of one of thecontract parties from derivative classification. The ASU also provides guidance under Topic 606 on the accounting for share-basednoncash consideration